Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R

Authors

Keywords

GLP-1, Liraglutide, Osteoclast, Osteoclastogenesis, Signalling pathway

Journal

Volume 130, Issue -, Pages 110523

Publisher

Elsevier BV

Online

2020-07-21

DOI

10.1016/j.biopha.2020.110523

Contact the author

Explore over 38,000 international journals covering a vast array of academic fields.

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now